Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) CFO William J. Peters sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, December 3rd. The stock was sold at an average price of $22.40, for a total transaction of $224,000.00. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Shares of NASDAQ:AMPH opened at $21.72 on Friday. The company has a market capitalization of $989.73 million, a P/E ratio of 107.35 and a beta of 1.42. The company has a current ratio of 2.02, a quick ratio of 1.34 and a debt-to-equity ratio of 0.10. Amphastar Pharmaceuticals Inc has a 1 year low of $14.40 and a 1 year high of $22.74.
Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its quarterly earnings data on Thursday, November 8th. The company reported $0.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.11 by $0.01. The business had revenue of $75.54 million for the quarter, compared to analysts’ expectations of $76.84 million. Amphastar Pharmaceuticals had a negative net margin of 2.33% and a positive return on equity of 2.80%. The firm’s quarterly revenue was up 30.5% compared to the same quarter last year. During the same period last year, the firm posted $0.07 earnings per share. As a group, equities analysts predict that Amphastar Pharmaceuticals Inc will post -0.06 EPS for the current fiscal year.
Several research analysts have recently commented on the stock. Jefferies Financial Group reaffirmed a “buy” rating and set a $26.00 target price on shares of Amphastar Pharmaceuticals in a report on Wednesday, November 14th. Zacks Investment Research cut shares of Amphastar Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, November 13th. Needham & Company LLC set a $25.00 target price on shares of Amphastar Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, November 9th. Wells Fargo & Co reissued a “buy” rating on shares of Amphastar Pharmaceuticals in a research note on Friday, November 9th. Finally, BidaskClub raised shares of Amphastar Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Thursday, October 18th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $23.60.
Large investors have recently made changes to their positions in the stock. Renaissance Technologies LLC increased its stake in Amphastar Pharmaceuticals by 76.6% in the second quarter. Renaissance Technologies LLC now owns 91,100 shares of the company’s stock valued at $1,390,000 after acquiring an additional 39,500 shares during the last quarter. BlackRock Inc. increased its stake in Amphastar Pharmaceuticals by 5.9% in the second quarter. BlackRock Inc. now owns 5,720,183 shares of the company’s stock valued at $87,291,000 after acquiring an additional 318,360 shares during the last quarter. SG Americas Securities LLC bought a new position in Amphastar Pharmaceuticals in the second quarter valued at approximately $161,000. Piedmont Investment Advisors LLC bought a new position in Amphastar Pharmaceuticals in the second quarter valued at approximately $128,000. Finally, Sei Investments Co. increased its stake in Amphastar Pharmaceuticals by 4.9% in the second quarter. Sei Investments Co. now owns 67,934 shares of the company’s stock valued at $1,037,000 after acquiring an additional 3,193 shares during the last quarter. 44.74% of the stock is currently owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: “Amphastar Pharmaceuticals Inc (AMPH) CFO William J. Peters Sells 10,000 Shares” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/12/07/amphastar-pharmaceuticals-inc-amph-cfo-william-j-peters-sells-10000-shares.html.
Amphastar Pharmaceuticals Company Profile
Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and internationally. It operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients.
Read More: What is a Reverse Stock Split?
Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.